CIK 0001658551 · Non-accelerated filer<br>Smaller reporting company
Amylyx Pharmaceuticals, Inc.
Sign in to watch- Ticker
- AMLX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 464600503
- Phone
- 617-682-0917
- Business address
- 55 CAMBRIDGE PARKWAY, SUITE 6W, CAMBRIDGE, MA, 02142
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $10,951,125
- in 9 filings, $8.0M under 10b5-1 plans
Net −$10,951,125. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Cohen Joshua B −$4.0M Co-Chief Executive Officer sold 4% of stake
- Klee Justin B. −$4.0M Co-Chief Executive Officer sold 4% of stake
- FRATES JAMES M −$1.6M Chief Financial Officer sold 18% of stake
- MILNE GEORGE M JR −$831K Director sold 4% of stake
- Bedrosian Camille L −$325K Chief Medical Officer sold 3% of stake
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-01-06 | Cohen Joshua B Co-Chief Executive Officer | Sale | −7,471 | $4.05 | $30K | 3,213,098 |
| 2024-12-02 | Bedrosian Camille L Chief Medical Officer | Sale | −5,421 | $5.54 | $30K | 138,380 |
| 2024-11-04 | Klee Justin B. Co-Chief Executive Officer | Option exercise | +63,690 | $1.57 | $100K | 3,184,259 |
| 2024-11-04 | Klee Justin B. Co-Chief Executive Officer | Option exercise · Stock Option (right to buy) | −63,690 | 36,310 | ||
| 2024-09-30 | Klee Justin B. Co-Chief Executive Officer | Sale | −18,589 | $3.20 | $59K | 3,120,569 |
| 2024-09-30 | Cohen Joshua B Co-Chief Executive Officer | Sale | −18,589 | $3.20 | $59K | 3,220,569 |
| 2024-09-30 | Bedrosian Camille L Chief Medical Officer | Sale | −11,442 | $3.20 | $37K | 143,801 |
| 2024-09-30 | Mazzariello Gina Chief Legal Officer | Sale | −8,709 | $3.20 | $28K | 142,768 |
| 2024-09-23 | Cohen Joshua B Co-Chief Executive Officer | Option exercise | +1,857 | $1.57 | $3K | 3,239,158 |
| 2024-09-23 | Cohen Joshua B Co-Chief Executive Officer | Option exercise · Stock Option (right to buy) | −1,857 | 0 | ||
| 2024-09-12 | Cohen Joshua B Co-Chief Executive Officer | Option exercise | +34,449 | $1.57 | $54K | 3,237,301 |
| 2024-09-12 | Cohen Joshua B Co-Chief Executive Officer | Option exercise · Stock Option (right to buy) | −34,449 | 1,857 | ||
| 2024-09-12 | FRATES JAMES M Chief Financial Officer | Purchase | +40,000 | $2.53 | $101K | 233,464 |
| 2024-09-05 | Firestone Karen Director | Purchase | +50,000 | $2.13 | $107K | 55,000 |
| 2024-09-03 | MILNE GEORGE M JR Director | Purchase | +100,000 | $2.20 | $220K | 858,571 |
| 2024-06-06 | FONTEYNE PAUL R. Director | Grant or award · Stock Option (right to buy) | +25,000 | 25,000 | ||
| 2024-06-06 | Firestone Karen Director | Grant or award · Stock Option (right to buy) | +25,000 | 25,000 | ||
| 2024-06-06 | Zeiher Bernhardt G Director | Grant or award · Stock Option (right to buy) | +5,753 | 5,753 | ||
| 2024-06-06 | MILNE GEORGE M JR Director | Grant or award · Stock Option (right to buy) | +25,000 | 25,000 | ||
| 2024-06-06 | Quimi Daphne Director | Grant or award · Stock Option (right to buy) | +25,000 | 25,000 |
Page 7 of 19 · 362 trades